Journal: Discover Oncology

Article Title: FKBP10 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma

doi: 10.1007/s12672-026-04604-1

Figure Lengend Snippet: FKBP10 expression profiles and prognostic significance in HCC. A Pan-cancer analysis of FKBP10 mRNA expression across tumor and normal tissues using the TIMER database. B FKBP10 mRNA expression in HCC and normal liver tissues from TCGA, analyzed via the UALCAN portal. C FKBP10 expression across liver cancer subtypes. D , E FKBP10 expression in tumors with different histological grades and nodal metastasis status, respectively. F FKBP10 protein expression levels in HCC versus normal liver tissues from the CPTAC dataset. G Immunohistochemical staining of FKBP10 protein in HCC and normal tissues from the HPA database. H , I Validation of FKBP10 mRNA ( H ) and protein ( I ) expression in paired tumor and adjacent normal tissues from clinical HCC samples. J Kaplan-Meier survival curves showing the overall survival difference between high and low FKBP10 expression groups in TCGA-HCC, analyzed via UALCAN. K Kaplan-Meier curves showing overall survival (OS) and disease-free survival (DFS) in high vs. low FKBP10 expression groups from a clinical HCC cohort

Article Snippet: Tissue sections were incubated overnight at 4 °C with fluorophore-conjugated primary antibodies against EpCAM (Proteintech, 21050-1-AP), α-SMA (Proteintech, 14395-1-AP), and FKBP10 (Proteintech, 12172-1-AP) in a humidified chamber.

Techniques: Expressing, Immunohistochemical staining, Staining, Biomarker Discovery

Journal: Discover Oncology

Article Title: FKBP10 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma

doi: 10.1007/s12672-026-04604-1

Figure Lengend Snippet: Functional enrichment analyses of FKBP10 and associated genes in HCC. A Protein–protein interaction (PPI) network of FKBP10 and its top 10 interacting proteins constructed using STRING. B KEGG and GO enrichment analyses of the top 50 FKBP10-interacting proteins. C Volcano plot showing differentially expressed genes (DEGs) between FKBP10-high and FKBP10-low groups in TCGA-LIHC ( P < 0.01, |log₂FC| > 1); top upregulated DEGs are labeled. D KEGG pathway enrichment analysis of the DEGs between FKBP10-high and FKBP10-low groups. E GO enrichment analysis of the DEGs, including biological process (BP), cellular component (CC), and molecular function (MF) categories. F GSEA showing pathways positively enriched in the FKBP10-high expression group

Article Snippet: Tissue sections were incubated overnight at 4 °C with fluorophore-conjugated primary antibodies against EpCAM (Proteintech, 21050-1-AP), α-SMA (Proteintech, 14395-1-AP), and FKBP10 (Proteintech, 12172-1-AP) in a humidified chamber.

Techniques: Functional Assay, Construct, Labeling, Expressing

Journal: Discover Oncology

Article Title: FKBP10 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma

doi: 10.1007/s12672-026-04604-1

Figure Lengend Snippet: Single-cell transcriptomic analysis of FKBP10 expression in HCC fibroblasts. A UMAP clustering of 44 cell clusters based on scRNA-seq datasets GSE189903 and GSE212046 . B Cell type annotation based on canonical marker genes. C UMAP plot displaying FKBP10 expression across cell types. D Bubble plot of representative marker genes for cell-type identification. E Subclustering of fibroblasts for further analysis. F Classification of fibroblasts into FKBP10⁺ and FKBP10⁻ subgroups. G Violin plot comparing FKBP10 expression in fibroblasts from HCC versus normal tissues. H Proportional distribution of fibroblast subclusters in tumor versus normal samples, revealing heterogeneity. I FKBP10 expression distribution in fibroblast subpopulations, enriched in tumor-derived fibroblasts. J , K KEGG ( J ) and GO ( K ) enrichment analyses of DEGs between FKBP10⁺ and FKBP10⁻ fibroblasts

Article Snippet: Tissue sections were incubated overnight at 4 °C with fluorophore-conjugated primary antibodies against EpCAM (Proteintech, 21050-1-AP), α-SMA (Proteintech, 14395-1-AP), and FKBP10 (Proteintech, 12172-1-AP) in a humidified chamber.

Techniques: Single Cell, Expressing, Marker, Derivative Assay

Journal: Discover Oncology

Article Title: FKBP10 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma

doi: 10.1007/s12672-026-04604-1

Figure Lengend Snippet: Cell–cell communication analysis of FKBP10⁺ CAFs in the HCC tumor microenvironment. A Number and strength of intercellular interactions among major cell types in HCC. B Communication network showing FKBP10⁺ fibroblasts as key signaling hubs. C Global overview of signaling pathways mediating cell-cell communication. D , E FKBP10⁺ fibroblasts demonstrate dominant interactions via collagen and laminin pathways, particularly with endothelial cells. F Representative immunofluorescence images of human HCC sections stained for FKBP10, α-SMA (CAFs), and EpCAM (HCC), with nuclei counterstained by DAPI. Merged images show prominent co-localization of FKBP10 with α-SMA–positive CAFs

Article Snippet: Tissue sections were incubated overnight at 4 °C with fluorophore-conjugated primary antibodies against EpCAM (Proteintech, 21050-1-AP), α-SMA (Proteintech, 14395-1-AP), and FKBP10 (Proteintech, 12172-1-AP) in a humidified chamber.

Techniques: Protein-Protein interactions, Immunofluorescence, Staining

Journal: Discover Oncology

Article Title: FKBP10 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma

doi: 10.1007/s12672-026-04604-1

Figure Lengend Snippet: Drug sensitivity and immune landscape associated with FKBP10 expression. A – E Correlation analysis between FKBP10 expression and drug activity z-scores (e.g., Apitolisib, PF-04691502, AZD5363, AZD-8055, Bleomycin) using CellMiner; comparison of predicted drug sensitivity between FKBP10-high and -low expression groups. F Immune cell infiltration profiles inferred via CIBERSORT for FKBP10-high vs. -low groups in TCGA-LIHC. G Differential expression of immune checkpoint genes between FKBP10-high and FKBP10-low groups

Article Snippet: Tissue sections were incubated overnight at 4 °C with fluorophore-conjugated primary antibodies against EpCAM (Proteintech, 21050-1-AP), α-SMA (Proteintech, 14395-1-AP), and FKBP10 (Proteintech, 12172-1-AP) in a humidified chamber.

Techniques: Expressing, Activity Assay, Comparison, Quantitative Proteomics

Journal: Discover Oncology

Article Title: FKBP10 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma

doi: 10.1007/s12672-026-04604-1

Figure Lengend Snippet: Additional drug response analysis based on FKBP10 expression. Scatter plots showing correlations between FKBP10 expression and drug activity z-scores; violin plots compare drug sensitivity between FKBP10-high and FKBP10-low expression groups. Data derived from the CellMiner database

Article Snippet: Tissue sections were incubated overnight at 4 °C with fluorophore-conjugated primary antibodies against EpCAM (Proteintech, 21050-1-AP), α-SMA (Proteintech, 14395-1-AP), and FKBP10 (Proteintech, 12172-1-AP) in a humidified chamber.

Techniques: Expressing, Activity Assay, Derivative Assay

Journal: Cell communication and signaling : CCS

Article Title: FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells.

doi: 10.1186/s12964-022-01033-9

Figure Lengend Snippet: Fig. 5 Proposed regulation of ligand dependent ALK2 activity in multiple myeloma cells. A ALK2 ligands such as BMP6, BMP9, and activin B signal via ALK2 preferably in complex with ACVR2A or ACVR2B. Activin A also binds to ALK2:ACVR2 but may either form a non-signaling complex (NSC) or an active signaling complex depending on the context. Addition of FK506 removes FKBP12 from the activation domain of ALK2 leading to increased ligand-induced SMAD1/5-activation. SMAD1/5-activation leads to myeloma cell apoptosis. B ALK3 ligands such as BMP2, BMP4, and BMP10, do not activate SMAD1/5 via ALK2 even in the presence of their preferred type II receptor BMPR2. It is unclear if the ligand can form an NSC with the receptors or not. Addition of FK506 removes FKBP12 from the activation domain of ALK2 leading to a dose-dependent ligand-induced SMAD1/5-activation and myeloma cell apoptosis. The figure was made with Biorender.com

Article Snippet: Recombinant human BMP2 (#355-BM), BMP4 (#314-BP), BMP6 (#507-BP), BMP9 (#3209-BP), BMP10 (#2926-BP), TGF-β1 (#240-B), and activin B (#659-AB-025) were from R&D Systems (BioTechne, Abingdon, UK).

Techniques: Activity Assay, Activation Assay

Journal: Cellular and molecular biology (Noisy-le-Grand, France)

Article Title: Homocysteine modulates CXCL10/CXCR3 axis activity to induce endothelial dysfunction.

doi: 10.14715/cmb/2024.70.2.28

Figure Lengend Snippet: Fig. 3. (A, B) qRT-PCR and Western blot analysis of CXCL10 and CXCR3 expression in HAECs treated with different concentrations of Hcy. (C) IHC analysis of the aorta in HHcy mice showing CXCL10 and CXCR3 expression. (D) qRT-PCR analysis of CXCL10 and CXCR3 expression in arterial endothelial cells.

Article Snippet: Additionally, HAECs were exposed to specific agents including Anti-CXCL10 antibodies (701225, Invitrogen, USA), Anti-CXCR3 antibodies (ab71864, Abcam, UK), IgG control antibodies (31154, Thermo Fisher, USA), NBI-74330 (a CXCR3 inhibitor, 4528, Tocris Bioscience, UK), and CXCL10 agonist (266-IP, R&D Systems, USA).

Techniques: Quantitative RT-PCR, Western Blot, Expressing